Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Evofem Biosciences Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
EVFM
Over the counter
2834
https://www.evofem.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Evofem Biosciences Inc
Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO
- Apr 18th, 2024 12:36 pm
Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023
- Mar 27th, 2024 12:36 pm
Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal
- Mar 20th, 2024 12:54 pm
For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy
- Mar 7th, 2024 12:54 pm
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023
- Feb 1st, 2024 1:00 pm
Washington State HCA Removes Prior Authorization for Hormone-Free "In the Moment" Contraceptive PHEXXI Ahead of Huskies vs. Wolverines Championship Game
- Jan 8th, 2024 1:30 pm
Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally
- Dec 12th, 2023 1:30 pm
Evofem Biosciences Announces Financial Results for the Third Quarter of 2023
- Nov 14th, 2023 11:56 am
Evofem Biosciences Announces Preliminary Results for the Third Quarter of 2023
- Oct 24th, 2023 11:36 am
Evofem to Participate in the Virtual Investor Ask the CEO Conference
- Oct 13th, 2023 3:36 pm
Evofem Announces Padagis Will Not Seek FDA Approval to Market a Generic Version of Phexxi® Until Evofem's Phexxi Patents Expire
- Sep 27th, 2023 12:47 pm
Evofem Biosciences Successfully Amends S.P.A. with Institutional Investor
- Sep 11th, 2023 12:00 pm
Evofem Biosciences Signs Non-Binding Letter of Intent to Enable Listing on a National Stock Exchange
- Aug 22nd, 2023 8:01 pm
Evofem Biosciences Announces Financial Results for the Second Quarter of 2023
- Aug 14th, 2023 9:00 pm
Evofem to Participate in the Virtual Investor Summer Spotlight Series
- Jul 6th, 2023 12:42 pm
Evofem Biosciences Announces Financial Results for the First Quarter of 2023
- Jun 16th, 2023 8:01 pm
Evofem Biosciences Announces Strong Preliminary Results for the First Quarter of 2023
- Jun 1st, 2023 12:36 pm
Evofem Biosciences Announces 1-for-125 Reverse Stock Split
- May 17th, 2023 8:50 pm
Evofem Biosciences Reports Year-End 2022 Financial Results and Provides Corporate Update
- Apr 28th, 2023 10:50 am
Scroll